Detalles de la búsqueda
1.
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
Lancet
; 383(9915): 413-23, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24183564
2.
Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial.
Am Heart J
; 169(1): 69-77, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25497250
3.
Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial.
Catheter Cardiovasc Interv
; 85(4): 524-31, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24753036
4.
Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.
Catheter Cardiovasc Interv
; 85(3): E76-82, 2015 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25339110
5.
Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
Catheter Cardiovasc Interv
; 85(1): 74-81, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24585502
6.
Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial.
Am Heart J
; 167(4): 445-51, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24655691
7.
Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial.
Catheter Cardiovasc Interv
; 82(3): 396-405, 2013 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23359390
8.
DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): rationale and study design of a randomized multicenter trial in a Dutch all-comers population.
Am Heart J
; 163(4): 557-62, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22520520
9.
Scanning electron microscopic assessment of coating irregularities and their precursors in unexpanded durable polymer-based drug-eluting stents.
Catheter Cardiovasc Interv
; 79(4): 644-53, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21805599
10.
Long-Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer-Generation Drug-Eluting Stents.
J Am Heart Assoc
; 7(3)2018 01 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29382666
11.
"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study.
JACC Cardiovasc Interv
; 11(5): 448-459, 2018 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29454724
12.
Five-Year Outcome After Implantation of Zotarolimus- and Everolimus-Eluting Stents in Randomized Trial Participants and Nonenrolled Eligible Patients: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Cardiol
; 2(3): 268-276, 2017 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28114618
13.
Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial.
EuroIntervention
; 12(4): 431-40, 2016 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26342469
14.
Outcome After Myocardial Infarction Treated With Resolute Integrity and Promus Element Stents: Insights From the DUTCH PEERS (TWENTE II) Randomized Trial.
Rev Esp Cardiol (Engl Ed)
; 69(12): 1152-1159, 2016 Dec.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-27595181
15.
Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
Clin Res Cardiol
; 105(3): 206-15, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26329584
16.
Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials.
JACC Cardiovasc Interv
; 9(6): 553-61, 2016 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-26947384
17.
Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial.
EuroIntervention
; 10(11): 1276-9, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25136888
18.
Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.
EuroIntervention
; 11(2): 180-7, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24602919
19.
Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II).
JACC Cardiovasc Interv
; 8(7): 889-99, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26003019
20.
Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.
Int J Cardiol
; 176(3): 885-90, 2014 Oct 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25168098